ALT-Q2: Long-acting blood clotting Factor VII
· Alteogen is developing a long-acting active form of coagulation factor VII (FVIIa), which employs our proprietary NexP™ technology for treating hemophilia. ALT-Q2 (FVIIa-NexP™) is a recombinant fusion protein of FVIIa and NexP™.
· Hemophilia is a bleeding disorder with a delayed clotting process. FVIIa is a bypass agent for treating hemophilia patients with inhibitory antibody against coagulation factor VIII or IX. Currently, NovoSeven (Novo Nordisk) dominates the FVIIa market. However, the half-life of NovoSeven drug is short (~ 2 h). Short half-life of the drug causes for patients to intake multiple doses before reaching hemostasis. ALT-Q2 has shown much longer half-life and better in vivo efficacy in animal studies among hemophilia mice. Pre-clinical GLP toxicology studies will be underway to prove its safety and efficacy.
| Research | Process | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|---|
| ALT-Q2 | Long-acting Factor Vlla |  |
|
||||
| Process Development in Progress | |||||||
| ALT-Q2 | Long-acting Factor Vlla |
|---|---|
| Process Development in Progress | |
| Research | |
| Process | |
| Pre-clinical | |
| Phase 1 | |
| Phase 2 | |
| Phase 3 | |